Gossamer Bio Inc (FRA:4GB)
€ 0.7705 0.0095 (1.25%) Market Cap: 182.56 Mil Enterprise Value: 39.46 Mil PE Ratio: 0 PB Ratio: 2.46 GF Score: 36/100

Gossamer Bio Inc to Discuss Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis Call Transcript

Oct 13, 2020 / 12:00PM GMT
Release Date Price: €8 (-27.27%)
Operator

Good morning. My name is Diana, and I will be your conference operator today. At this time, I would like to welcome everyone to the Gossamer GB Phase II Results Conference Call. (Operator Instructions)

At this time, I would like to turn the conference over to Mr. Bryan Giraudo, Chief Financial Officer. Sir, you may begin.

Bryan Giraudo
Gossamer Bio, Inc. - CFO

Thank you, operator, and thank you all for joining us this morning. I am joined on today's call by Gossamer Bio's Co-Founder and Chief Executive Officer, Dr. Sheila Gujrathi; and Vice President of Clinical Development and Medical Lead for the GB001 program, Dr. Hector Ortega.

Earlier this morning, Gossamer Bio issued a press release announcing GB001 top line results from its Phase II LEDA study in patients with moderate to severe eosinophilic asthma and its Phase II TITAN study in patients with chronic rhinosinusitis.

Please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot